DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2005; 130(45): 2579-2584DOI: 10.1055/s-2005-922037 CME Nephrologie / Pharmakologie © Georg Thieme Verlag Stuttgart · New York Nephrotoxische Arzneimittel Nephrotoxic drugsD. Czock1 , U. Häußler1 , C. Aymanns1 , F. Keller1 1Nephrologie, Medizinische Universitätsklinik, Ulm Recommend Article Abstract Schlüsselwörter CME - Nephrologie - Pharmakologie Full Text References Literatur 1 Agrawal M, Stouffer G A. Contrast induced nephropathy after angiography. Am J Med Sci. 2002; 323 252-258 2 Anderson B J, Woollard G A, Holford N HG. Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. Eur J Clin Pharmacol. 2001; 57 559-569 3 Bader B D, Berger E D, Heede M B. et al . What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?. Clin Nephrol. 2004; 62 1-7 4 Birck R, Krzossok S, Markowetz F. et al . Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003; 362 598-603 5 Chang E J, Mun K C. Effect of epigallocatechin gallate on renal function in cyclosporine-induced nephrotoxicity. Transplant Proc. 2004; 36 2133-2134 6 Cheng H F, Harris R C. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005; 11 1795-1804 7 Deray G, Martinez F, Katlama C. et al . Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol. 1989; 9 316-321 8 Elseviers M M, Waller I, Nenoy D. et al . Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Analgesic Nephropathy Network of Europe. Nephrol Dial Transplant. 1995; 10 808-814 9 Elseviers M M, De Broe M E. Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance abuse?. Drug Saf. 1999; 20 15-24 10 Fillastre J P, Druet P, Mery J P. Proteinuric nephropathies associated with drugs and substances of abuse. Dekker, New York In The nephrotic syndrome (ed. Cameron JS, Glassock RJ) 1988: 697-744 11 Gitlin M. Lithium and the kidney: an updated review. Drug Saf. 1999; 20 231-243 12 Kadikoylu G, Bolaman Z, Demir S. et al . The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol. 2004; 23 29-34 13 Kuypers D R, Neumayer H H, Fritsche L. et al . Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomised placebo-controlled 2-year study. Transplantation. 2004; 78 1204-1211 14 Lin J, Bonventre J V. Prevention of radiocontrast nephropathy. Curr Opin Nephrol Hypertens. 2005; 14 105-110 15 Lukas R, Eren A, Zellner D. et al . Furosemide after contrast media does no harm to the kidneys and allows for preventive hydration. Perfusion. 2003; 16 326-333 16 Merten G J, Burgess W P, Gray L V, Holleman J H, Roush T S, Kowalchuk G J, Bersin R M, Van Moore A, Simonton C A, Rittase R A, Norton H J, Kennedy T P. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004; 291 2328-2334 17 Mueller C, Buerkle G, Buettner H J. et al . Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimes in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002; 162 329-336 18 Murphy S W, Barrett B J, Parfrey P S. Contrast nephropathy. J Am Soc Nephrol. 2000; 11 177-182 19 Nisar S, Feinfeld D A. N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity. Ren Fail. 2002; 24 529-533 20 Nishino Y, Takemura S, Minamiyama Y. et al . Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radic Res. 2003; 37 373-379 21 Olsen K M, Rudis M I, Rebuck J A. et al . Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med. 2004; 32 1678-1682 22 Ortiz M, Mon C, Fernandez M J. et al . Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib. Nefrologia. 2005; 25 39-43 23 Parfrey P S, Griffiths S M, Barrett B J. et al . Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med. 1989; 320 143-149 24 Parlakpinar H, Tasdemir S, Polat A. et al . Protective effect of chelerythrine on gentamicin-induced nephrotoxicity. Cell Biochem Funct. 2004; 25 Potter J L, Krill C E. Acyclovir crystalluria. Pediatr Infect Dis. 1986; 5 710-712 26 Rudnick M R, Goldfarf S, Wexler l. et al . Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995; 47 254-261 27 Santoso J T, Lucci J A, Coleman R L. et al . Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomised trial. Cancer Chemother Pharmacol. 2003; 52 13-18 28 Sawyer M H, Webb D F, Balow J E. et al . Acyclovir induced renal failure: clinical course and histology. Am J Med. 1988; 84 1067-1071 29 Schadeli F, Marti H P, Frey F J. et al . Population pharmacokinetic model to predict steady-state exposure to once-daily Cyclosporin microemulsion in renal transplant recipients. Clin Pharmacokinet. 2002; 41 59-69 30 Schwarz A. Systematik der Nephrotoxizität. Wissenschaftliche Verlagsgesellschaft, Stuttgart In Nierenfunktion und Arzneimittel (ed. Deuber HJ, Keller F, Schwarz A) 2001: 150-259 31 Schwarz A, Krause P H, Kunzendorf U. et al . The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol. 2003; 54 179-190 32 Smith E J, Light J A, Filo R S. et al . Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients. J Am Med Assoc. 1980; 244 360-361 33 Sturmer T, Erb A, Keller F, Gunther K P, Brenner H. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am J Med. 2001; 1111 521-527 34 Tepel M, van der Giet M, Schwarzfeld C. et al . Prevention of radiographic contrast agent-induced reductions in renal functions by acetylcysteine. N Engl J Med. 2000; 343 180-184 35 World M J, Stevens P E, Ashton M A. et al . Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant. 1996; 11 614-621 Prof. Dr. Frieder Keller Sektionsleiter Nephrologie, Medizinische Universitätsklinik Robert Koch-Straße 8 89070 Ulm Phone: 0731/50024341 Fax: 0731/50024483 Email: frieder.keller@uni-ulm.de